Tissue Regeneration Systems, Inc. has received FDA 510K approval for its Cranial Bone Void Filler product, indicated for use in the repair of neurosurgical burr holes. This is first of a family of craniomaxillofacial surgery products being developed by TRS that incorporate the company’s novel skeletal reconstruction and bone regeneration technology platform.
Tissue Regeneration Systems Receives 510K Approval (via
PR Newswire)
ANN ARBOR, Mich., Aug. 26, 2013 /PRNewswire/ — Tissue Regeneration Systems, Inc. (“TRS”) today announced that it has received 510K approval from the U.S. Food and Drug Administration for its Cranial Bone Void Filler product, indicated for use in the…
published: August 27, 2013 in: News